Yang K, Yu M
Lawson Research Institute, Department of Obstetrics and Gynecology, University of Western Ontario, St Joseph's Health Centre, London, Canada.
J Steroid Biochem Mol Biol. 1994 Jun;49(2-3):245-50. doi: 10.1016/0960-0760(94)90016-7.
We have previously identified a unique 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) transcript in the ovine kidney. To examine whether this is indicative of a distinct isoform with respect to enzymatic activity, we studied and compared the characteristics of 11 beta-HSD activity in the ovine liver and kidney. 11 beta-HSD activity was determined by a radiometric conversion assay using cortisol and cortisone as physiological substrates. Although in both liver and kidney, the enzyme was localized by subcellular fractionation in the microsomes, the renal 11 beta-HSD displayed distinct characteristics in that it expressed only dehydrogenase activity and utilized almost exclusively NAD as cofactor (the respective activity in the presence of NAD and NADP was 190 +/- 26 and 12 +/- 2 pmol/min/mg protein). By contrast, the liver enzyme contained both dehydrogenase and reductase activities, and displayed preference for NADP and NADPH, respectively. Furthermore, with cortisol as substrate, the kidney 11 beta-HSD had a Km of 68 +/- 7 nM which was over 100 times lower than the hepatic enzyme (8 +/- 1 microM). In addition, the renal 11 beta-HSD activity was inhibited in a dose-dependent fashion by both carbenoxolone, a potent inhibitor of 11 beta-HSD, and the end product cortisone, whereas the liver enzyme showed little inhibition by either substance. In summary, these results provide strong evidence for the existence of distinct isoforms of 11 beta-HSD with respect to enzymatic activity in the ovine liver and kidney. In addition, the characteristics of the kidney enzyme closely resemble those of that described previously in the rabbit renal aldosterone target cells, and thus further demonstrating the presence of an isoform of 11 beta-HSD distinct from the NADP-dependent enzyme purified and cloned from the rat liver.
我们之前在绵羊肾脏中鉴定出一种独特的11β-羟基类固醇脱氢酶(11β-HSD)转录本。为了研究这是否表明存在具有独特酶活性的同工型,我们对绵羊肝脏和肾脏中11β-HSD的活性特征进行了研究和比较。11β-HSD活性通过以皮质醇和可的松作为生理底物的放射性转化测定法来确定。虽然在肝脏和肾脏中,该酶通过亚细胞分级分离定位于微粒体中,但肾脏中的11β-HSD表现出独特的特征,即它仅表现出脱氢酶活性,并且几乎仅利用NAD作为辅因子(在存在NAD和NADP时各自的活性分别为190±26和12±2 pmol/分钟/毫克蛋白)。相比之下,肝脏中的酶同时具有脱氢酶和还原酶活性,并且分别对NADP和NADPH表现出偏好。此外,以皮质醇为底物时,肾脏中的11β-HSD的Km为68±7 nM,比肝脏中的酶低100多倍(8±1 μM)。此外,强效11β-HSD抑制剂甘草次酸和终产物可的松均以剂量依赖性方式抑制肾脏中的11β-HSD活性,而肝脏中的酶对这两种物质几乎没有抑制作用。总之,这些结果为绵羊肝脏和肾脏中存在具有独特酶活性的11β-HSD同工型提供了有力证据。此外,肾脏中该酶的特征与先前在兔肾醛固酮靶细胞中描述的特征非常相似,从而进一步证明存在一种与从大鼠肝脏中纯化和克隆的依赖NADP的酶不同的11β-HSD同工型。